Biopôle is pleased to welcome MoleSense to the Vanguard Accelerator programme. This unique six-month initiative, delivered in collaboration with Swiss Healthcare Startups, is designed to support high-potential digital health ventures at critical stages in their development. Through tailored mentorship, actionable feedback and access to a broad network of healthcare and industry stakeholders, the programme helps companies to refine their strategy, validate their technology and accelerate the journey from innovation to market-readiness.

Founded in 2025 by EPFL alumni Gian Luca Barbruni and Ata Golparvar, MoleSense is advancing women’s healthcare through molecular wearable technology. Moving beyond tracking vital signs, its core innovation is a new class of medical devices that continuously and non-invasively monitor biochemical markers, such as proteins and hormones, in real time. By supporting early diagnostics and improved clinical decision-making, MoleSense aims to enable more proactive, preventive care for women, with an initial focus on high-risk pregnancies – an area that has historically been underserved by medical technology.

Through the Vanguard Accelerator, MoleSense specifically aims to accelerate the development its molecular wearable for maternity care, transitioning from the R&D stage to a market-ready product strategy. ‘We want to validate our commercialisation assumptions with real healthcare stakeholders, while refining our product–market fit and messaging for early-adopting hospitals,’ explains MoleSense CEO Gian Luca Barbruni. ‘The Vanguard Accelerator offers an ideal environment to strengthen our network for partnerships and future scale-up, including clinical access, pilot deployments and collaborations with established medtech and pharmaceutical players.’

Being based at Biopôle in the StartLab further reinforces this momentum at a critical stage of the company’s development. ‘We are embedded in one of Switzerland’s strongest life sciences environments, with proximity to our clinical partners in the Lausanne University Hospital (CHUV) and a dense community of biotech innovators,’ adds Ata Golparvar, Chief Technology Officer at MoleSense. ‘Operationally, it’s also a major lever for speed and capital efficiency, with a flexible lab infrastructure and innovation-driven community, which make it easier to recruit talent, meet collaborators and build partnerships.’

By joining the Vanguard Accelerator, MoleSense becomes part of a growing community of ambitious digital health ventures committed to translating innovation into tangible healthcare impact. Former participants of the programme include Undae Science, DigeHealth, Virtuosis, PhenomX, biped.ai, Gabi SmartCare, Impli and Neuria.